Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication

BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of Helicobacter pylori. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Yong Hwan, Jeon, Seong Woo, Nam, Su Youn, Lee, Dong Wook, Park, Ji Hey, Bae, Hui Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338248/
https://www.ncbi.nlm.nih.gov/pubmed/37369525
http://dx.doi.org/10.3904/kjim.2022.345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338248/
https://www.ncbi.nlm.nih.gov/pubmed/37369525
http://dx.doi.org/10.3904/kjim.2022.345

Ejemplares similares